Synthesis and pharmacological properties of new, GABA uptake inhibitors

Pharmacological Reports

Volumn 64, Issue 4, 2012, Pages 817-833

  Sałat, Kinga ^a   Wiȩckowska, Anna ^a   Wiȩckowski, Krzysztof ^a   Höfner, Georg C ^b   Kamiñski, Jacek ^a   Wanner, Klaus T ^b   Malawska, Barbara ^a   Filipek, Barbara ^a   Kulig, Katarzyna ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Amino acids; Butanamides; Four plate test; GABA uptake inhibitors; MGAT1 4; Motor coordination; Pain models

Indexed keywords

2 (4 BENZHYDRYLPIPERAZIN 1 YL) 4 (1,3 DIOXOISOINDOLIN 2 YL) N (4 FLUOROBENZYL)BUTANAMIDE; 2 (4 BENZHYDRYLPIPERAZIN 1 YL) 4 (1,3 DIOXOISOINDOLIN 2 YL) N (4 METHYLBENZYL)BUTANAMIDE; 2 (4 BENZHYDRYLPIPERAZIN 1 YL) N (4 BENZYL) 4 (1,3 DIOXOISOINDOLIN 2 YL)BUTANAMIDE; 2 (4 BENZHYDRYLPIPERAZIN 1 YL) N (4 CHLOROBENZYL) 4 (1,3 DIOXOISOINDOLIN 2 YL)BUTANAMIDE; 2 [4 OXO 3 (4 PHENYLPIPERAZIN 1 YL) 4 (PYRRILIDIN 1 YL)BUTYL]ISOINDOLINE 1,3 DIONE; 4 (1,3 DIOXOISOINDOLIN 2 YL) 2 [4 (4 FLUOROPHENYL)PIPERAZIN 1 YL] N 4 FLUOROBENZYLBUTANAMIDE; 4 (1,3 DIOXOISOINDOLIN 2 YL) 2 [4 (4 FLUOROPHENYL)PIPERAZIN 1 YL] N 4 METHYLBENZYLBUTANAMIDE; 4 (1,3 DIOXOISOINDOLIN 2 YL) 2 [4 (4 METHOXYPHENYL)PIPERAZIN 1 YL] N (4 METHYLBENZYL)BUTANAMIDE; 4 (1,3 DIOXOISOINDOLIN 2 YL) N (4 FLUOROBENZYL) 2 [4 (4 METHOXYPHENYL)PIPERAZIN 1 YL]BUTANAMIDE; 4 (1,3 DIOXOISOINDOLIN 2 YL) N (4 METHOXYBENZYL) 2 (4 PHENYLPIPERAZIN 1 YL)BUTANAMIDE; 4 (1,3 DIOXOISOINDOLIN 2 YL) N PHENYL 2 (4 PHENYLPIPERAZIN 1 YL)BUTANAMIDE; 4 AMINO 2 (4 BENZHYDRYLPIPERAZIN 1 YL)BUTANOIC ACID; 4 AMINO 2 (4 PHENYLPIPERAZIN 1 YL)BUTANOIC ACID; 4 AMINO 2 [4 (4 FLUOROPHENYL)PIPERAZIN 1 YL]BUTANOIC ACID; 4 AMINO 2 [4 (4 METHOXYPHENYL)PIPERAZIN 1 YL]BUTANOIC ACID; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID CARRIER; 4 AMINOBUTYRIC ACID UPTAKE INHIBITOR; DIAZEPAM; INDOMETACIN; MORPHINE; N (2 CHLOROBENZYL) 4 (1,3 DIOXOISOINDOLIN 2 YL) 2 (4 PHENYLPIPERAZIN 1 YL)BUTANAMIDE; N (4 CHLOROBENZYL) 4 (1,3 DIOXOISOINDOLIN 2 YL) 2 [4 (4 FLUOROPHENYL)PIPERAZIN 1 YL]BUTANAMIDE; N (4 CHLOROBENZYL) 4 (1,3 DIOXOISOINDOLIN 2 YL) 2 [4 (4 METHOXYPHENYL)PIPERAZIN 1 YL]BUTANAMIDE; N BENZYL 4 (1,3 DIOXOISOINDOLIN 2 YL) 2 [4 (4 FLUOROPHENYL)PIPERAZIN 1 YL]BUTANAMIDE; N BENZYL 4 (1,3 DIOXOISOINDOLIN 2 YL) 2 [4 (4 METHOXYPHENYL)PIPERAZIN 1 YL]BUTANAMIDE; TIAGABINE; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG SYNTHESIS; LOCOMOTION; MALE; MOUSE; NONHUMAN; PAIN; TRANQUILIZING ACTIVITY;

EID: 84867675634     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(12)70877-0     Document Type: Article

References (60)

1. Baldwin D, Woods R, Lawson R, Taylor D: Efficacy of drug treatments for generalised anxiety disorder: system-atic review and meta-analysis. BMJ, 2011, doi: 10.1136/bmj.d1199.
2. Boissier JR, Tardy J, Divierres JC: A new simple method to explore the tranquilizing action: the chimney test (French). Med Exp, 1960, 3, 81-84.
3. BourinM,Masse F, Dailly E, HascoëtM: Anxiolytic-like effect ofmilnacipran in the four-plate test inmice:mechanismof action. Pharmacol BiochemBehav, 2005, 81, 645-656. (Pubitemid 40973787)
4. Bowery NG, Smart TG: GABA and glycine as neurotransmitters: a brief history. Br J Pharmacol, 2006, 147, S109-S119. (Pubitemid 43077268)
5. CastelliMP:Multi-faceted aspects of gamma-hydroxybutyric acid: a neurotransmitter, therapeutic agent and drug of abuse. Mini Rev Med Chem, 2008, 8, 1188-1202.
6. Cazalets JR, Bertrand S, Sqalli-Houssaini Y, Clarac F: GABAergic control of spinal locomotor networks in the neonatal rat. Ann NY Acad Sci, 1998, 860, 168-180. (Pubitemid 29045968)
7. Chiu CS, Brickley S, Jensen K, Southwell A, McKinney S, Cull-Candy S, Mody I, Lester HA: GABA transporter deficiency causes tremor, ataxia, nervousness, and increased GABA-induced tonic conductance in cerebellum. J Neurosci, 2005, 25, 3234-3245. (Pubitemid 40463559)
8. Chrooeciñska-Krawczyk M, Ratnaraj N, Patsalos PN, Czuczwar SJ: Effect of caffeine on anticonvulsant effects of oxcarbazepine, lamotrigine and tiagabine in a mouse model of generalized tonic-clonic seizures. Pharmacol Rep, 2009, 61, 819-826.
9. Clausen RP, Frølund B, Larsson OM, Schousboe A, Krogsgaard-Larsen P, White HS: A novel selective g-aminobutyric acid transport inhibitor demonstrated a functional role for GABA transporter subtype GAT2/BGT-1 in the CNS. Neurochem Int, 2006, 48, 637-642.
10. Cope DW, Di Giovanni G, Fyson SJ, Orban G, Errington AC, Lorincz ML, Gould TM et al.: Enhanced tonic GABAA inhibition in typical absence epilepsy. Nat Med, 2009, 15, 1392-1398.
11. Czapinski P, Blaszczyk B, Czuczwar SJ:Mechanisms of action of antiepileptic drugs. Curr TopMed Chem, 2005, 5, 3-14. (Pubitemid 40202106)
12. Dalby NO, Thomsen Ch, Fink-Jensen A, Lundbeck J, Sokilde B, Man CM, Sorensen PO, Meldrum B: Anticonvulsant properties of two GABA uptake inhibitors NNC 05-2045 and NNC 05-2090, not acting preferentially on GAT-1. Epilepsy Res, 1997, 28, 51-61. (Pubitemid 27306794)
13. Dalby NO: Inhibition of g-aminobutyric acid uptake: anatomy, physiology and effects against epileptic seizures. Eur J Pharmacol, 2003, 479, 127-137.
14. Di Lio A, Benke D, Besson M, Desmeules J, Daali Y, Wang ZJ, Edwankar R et al.: HZ166, a novel GABAA receptor subtype-selective benzodiazepine site ligand, is antihyperalgesic in mouse models of inflammatory and neuropathic pain. Neuropharmacology, 2011, 60, 626-632.
15. Eddy N, Leimbach D: Synthetic analgesics. II. Dithienylbutenyl - and dithienylbutylamines. J Pharmacol Exp Ther, 1953, 107, 385-393.
16. Ettinger AB, Argoff CE: Use of antiepileptic drugs for non-epileptic conditions: psychiatric disorders and chronic pain. Neurotherapeutics, 2007, 4, 75-83. (Pubitemid 46110806)
17. Gajcy K, Lochynski S, Librowski T: A role of GABA analogues in the treatment of neurological diseases. Curr Med Chem, 2010, 17, 2338-2347.
18. GiardinaWJ, Decker MW, Porsolt RD, Roux S, Collins SD, Kim DJB, Bannon AW: An evaluation of the GABA uptake blocker tiagabine in animal models of neuropathic and nociceptive pain. Drug Dev Res, 1998, 44, 106-113. (Pubitemid 28452882)
19. Gowin JL, Green CE, Alcorn JL, Swann AC, Moeller FG, Lane SD: Chronic tiagabine administration and aggressive responding in individuals with a history of substance abuse and antisocial behavior. J Psychopharmacol, 2012, 26, 982-993.
20. Höfner G,Wanner KT: Using short columns to speed up LC-MS quantification inMS binding assays. J Chromatogr B Analyt Technol Biomed Life Sci, 2010, 878, 1356-1364.
21. Hunskaar S, Hole K: The formalin test in mice: dissociation between inflammatory and non-inflammatory pain. Pain, 1987, 30, 103-114. (Pubitemid 17094194)
22. Ipponi A, Lamberti C, Medica A, Bartolini A, Malmberg-Aiello P: Tiagabine antinociception in rodents depends on GABAB receptor activation: parallel antinociception testing and medial thalamus GABA microdialysis. Eur J Pharmacol, 1999, 368, 205-211. (Pubitemid 29117141)
23. Iversen L: Neurotransmitter transporters and their impact on the development of psychopharmacology. Br J Pharmacol, 2006, 147; S82-S88.
24. Johannessen LC: Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs, 2008, 22, 27-47.
25. Kragler A, Höfner G, Wanner KT: Synthesis and biological evaluation of aminomethylphenol derivatives as inhibitors of the murine GABA transporters mGAT1- mGAT4. Eur J Med Chem, 2008, 43, 2404-2411.
26. Kulig K, Wiêckowski K, Wiêckowska A, Gajda J, Pochwat B, Höfner GC, Wanner KT, Malawska B: Synthesis and biological evaluation of the new amides of 2-substituted 4-hydroxybutyric acid derivatives as GABA uptake inhibitors. Eur J Med Chem, 2011, 46, 183-190.
27. Laughlin TM, Tram KV, Wilcox GL, Birnbaum AK: Comparison of antiepileptic drugs tiagabine, lamotrigine, and gabapentin in mouse models of acute, prolonged and chronic nociception. J Pharmacol Exp Ther, 2002, 302, 1168-1175. (Pubitemid 34920240)
28. Lewin L, Mattsson MO, Sellström A: Inhibition of transporter mediated gamma-aminobutyric acid (GABA) release by SKF 89976-A, a GABA uptake inhibitor, studied in a primary neuronal culture from chicken. Neurochem Res, 1992, 17, 577-584.
29. Lieving LM, Cherek DR, Lane SD, Tcheremissine OV, Nouvion SO: Effects of acute tiagabine administration on aggressive responses of adult male parolees. J Psychopharmacol, 2008, 22, 144-152. (Pubitemid 351322863)
30. Litchfield JT, Wilcoxon E: A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther, 1949, 96, 99-113.
31. Liu GX, Cai GQ, Cai YQ, Sheng ZJ, Jiang J, Mei Z, Wang ZG et al.: Reduced anxiety and depression-like behaviors in mice lacking GABA transporter subtype I. Neuropsychopharmacology, 2007, 32, 1531-1539.
32. £uszczki JJ, Czuczwar SJ: Dose-response relationship analysis of vigabatrin doses and their antinociceptive effects in the hot-plate test in mice. Pharmacol Rep, 2008, 60, 409-414.
33. Luszczki JJ, Czuczwar SJ: Isobolographic characterization of interactions between vigabatrin and tiagabine in two experimental models of epilepsy. Prog Neuropsychopharmacol Biol Psychiatry, 2007, 31, 529-538.
34. Łuszczki JJ, Kołacz A, Wojda E, Czuczwar M, Przesmycki K, Czuczwar SJ: Synergistic interaction of gabapentin with tiagabine in the hot-plate test in mice: an isobolographic analysis. Pharmacol Rep, 2009,61, 459-467.
35. Luszczki JJ, Swiader M, Parada-Turska J, Czuczwar SJ: Tiagabine synergistically interacts with gabapentin in the electroconvulsive threshold test in mice. Neuropsychopharmacology, 2003, 28, 1817-1830. (Pubitemid 41070847)
36. Madsen K, White HS, Clausen RP, Frølund B, Larsson OM, Krogsgaard-Larsen P, Schousboe A: Functional and pharmacological aspects of GABA transporters. Handbook of Neurochemistry and Molecular Neurobiology. Neural Membranes and Transport. Springer Science + Business Media, LLC, New York, 2007.
37. Madsen KK, Clausen RP, Larsson OM, Krogsgaard- Larsen P, Schousboe A, White HS: Synaptic and extrasynaptic GABA transporters as targets for anti-epileptic drugs. J Neurochem, 2009, 109, 139-144.
38. Madsen KK, White HS, Schousboe A: Neuronal and non-neuronal GABA transporters as targets for antiepileptic drugs. Pharmacol Ther, 2010, 125, 394-401.
39. Malawska B, Zejc A: Search for new anticonvulsant compounds. Part 1: Synthesis, physicochemical and anticonvulsant properties of new derivatives of alpha-amino- gamma-phthalimidobutyric acid. Pharmazie, 1995, 50, 722-725.
40. Manzanares J, Julian MD, Carrascosa A: Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes. Curr Neuropharmacol, 2006, 4, 239-257.
41. Meldrum BS, Rogawski MA: Molecular targets for antiepileptic drug development. Neurotherapeutics, 2007, 4, 18-61. (Pubitemid 46107329)
42. Narita M, Niikura K, Nanjo-Nikura K, Narita M, Furuya M, Yamashita A, Saeki M et al.: Sleep disturbances in a neuropathic pain-like condition in the mouse are associated with altered GABAergic transmission in the cingulate cortex. Pain, 2011, 152, 1358-1372.
43. Pollack MH, Roy-Byrne PP, Van Ameringen M, Snyder H, Brown C, Ondrasik J, Rickels K: The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebocontrolled study. J Clin Psychiatry, 2005, 66, 1401-1408. (Pubitemid 41779538)
44. Rogawski MA, Loescher W: The neurobiology of antiepileptic drugs for the treatment of non-epileptic conditions. Nat Med, 2004, 10, 685-692. (Pubitemid 38937632)
45. Rosenthal M: Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control. J Clin Psychiatry, 2003, 64, 1245-1249.
46. Salat K, Kulig K: GABA transporters as targets for new drugs. Fut Med Chem, 2011, 3, 211-222.
47. Sałat K, Kulig K, Sałat R, Filipek B, Malawska B: Analgesic and anticonvulsant activity of new derivatives of 2-substituted 4-hydroxybutanamides in mice. Pharmacol Rep, 2012, 64, 102-112.
48. Schwartz TL, Nihalani N: Tiagabine in anxiety disorders. Expert Opin Pharmacother, 2006, 7, 1977-1987. (Pubitemid 44489370)
49. Spina E, Perugi G: Antiepileptic drugs: indications other than epilepsy. Epileptic Disord, 2004, 6, 57-75. (Pubitemid 38808120)
50. Shin YH, Jung OM, Nah JJ, Nam KY, Kim CY, Nah SY: Ginsenosides that produce differentia antinociception in mice. Gen Pharmacol, 1999, 32, 653-659.
51. Smith CGS, Bowery NG, Whitehead KJ: GABA transporter type 1 (GAT-1) uptake inhibition reduces stimulated aspartate and glutamate release in the dorsal spinal cord in vivo via different GABAergic mechanisms. Neuropharmacology, 2007, 53, 975-981. (Pubitemid 350137395)
52. Soudijn W, van Wijngaarden I: The GABA transporter and its inhibitors. Curr Med Chem, 2000, 7, 1063-1079.
53. Thoeringer CK, Erhardt A, Sillaber I, Mueller MB, Ohl F, Holsboer F, Keck ME: Long-term anxiolytic and antidepressant-like behavioural effects of tiagabine, a selective GABA transporter-1 (GAT-1) inhibitor, coincide with a decrease in HPA system activity in C57BL/6 mice. J Pharmacol, 2010, 24, 733-743.
54. Thoeringer CK, Ripke S, Unschuld PG, Lucae S, Ising M, Bettecken T, Uhr M et al.: The GABA transporter 1 (SLC6A1): a novel candidate gene for anxiety disorders. J Neural Transm, 2009, 116, 649-657.
55. Thomsen C, Sorensen PO, Egebjerg J: 1-(3-(9H-carbazol- 9-yl)-1-propyl)-4-(2-methoxyphenyl)-4- piperidinol, a novel subtype selective inhibitor of the mouse type II GABA-transporter. Br J Pharmacol, 1997, 120, 983-985. (Pubitemid 27122632)
56. Tjølsen A, Berge OG, Hunskaar S, Rosland JH, Hole K: The formalin test: an evaluation of the method. Pain, 1992, 51, 5-17.
57. White HS, Watson WP, Hansen SL, Slough S, Perregaard J, Sarup A, Bolvig T et al.: First demonstration of a functional role for central nervous system betaine/g-aminobutyric acid transporter (mGAT2) based on synergistic anticonvulsant action among inhibitors of mGAT1 and mGAT2. J Pharmacol Exp Ther, 2005, 312, 866-874. (Pubitemid 40189590)
58. Wilson SG, Bryant CD, Lariviere WR, Olsen MS, Giles BE, Chesler EJ, Mogil JS: The heritability of antinociception II: pharmacogenetic mediation of three over-the- counter analgesics in mice. J Pharmacol Exp Ther, 2003, 305, 755-764. (Pubitemid 36459197)
59. Zeilhofer HU, Möhler H, Di Lio A: GABAergic analgesia: new insights from mutant mice and subtype-selective agonists. Trends Pharmacol Sci, 2009, 30, 397-402.
60. Zepperitz C, Höfner G,Wanner KT:MS-binding assays: kinetic, saturation, and competitive experiments based on quantitation of bound marker as exemplified by the GABA transporter mGAT1. ChemMed Chem, 2006, 1, 208-217. (Pubitemid 43700301)